Ischemia-reperfusion injury (IR) is the prime culprit in many clinical entities. In the most basic sense it is the injury sustained after an ischemic event and subsequent restoration of blood flow far surpassing that expected by ischemia alone. Reperfusion injury is the inflammatory response to a hypoxic insult. It often marks and defines the severity of myocardial infarction, cerebral ischemic events, intestinal ischemia, and many aspects of vascular surgery, trauma, and transplantation. Due to its prevalence and ease of abstraction, there are many models of reperfusion injury and even more avenues of study. Despite this research effort there is still a vast clinical challenge posed by the many facets of ischemia-reperfusion injury. However, in recent years much has been done to advance our understanding of the basic mechanisms behind this clinical enigma. It is this knowledge that will lead us to practical clinical solutions.
Intestinal ischemia-reperfusion injury
We have recently championed the model of intestinal ischemia-reperfusion injury due to its immediate clinical relevance as well as the ease with which it can be studied. Intestinal ischemiareperfusion remains a common, clinical problem with a reported mortality of 80-90%, for which there is currently little useful therapy other than surgical intervention and supportive care (1) . It is often encountered as a spontaneous event due to embolus, thrombosis, or torsion. It may also be iatrogenic in etiology occurring as an unavoidable sequela of thoraco-abdominal aortic aneurysm surgery, cardiac surgery, or in the unique case of intestinal transplant surgery. It is also encountered in trauma and burn patients when intestinal hypoperfusion is corrected by resuscitation. Utilizing rat and mouse models of intestinal ischemia-reperfusion, we have recently defined the early mediators of this process. We believe that this inflammatory event relates to action of the innate immune system as it responds to newly altered tissue as non-self and is dependent on natural antibody and complement. concurrent rise in intestinal temperature due to this hyperemia. Patients will complain of severe pain, classically described as out of proportion to physical exam. Ifunattended this injury will lead to symptoms consistent with severe peritonitis. Ultimately, if enough time elapses, there is intraluminal hemorrhage, intravascular thrombosis, and finally infarction requiring surgical resection. Histologically, there is an acute inflammatory cell infiltrate characterized by polymorphonuclear leukocytes. The mucosa demonstrates villus swelling and lifting of the epithelium due to. edema, followed by necrosis starting at the apex of the villi, resulting in intraluminal hemorrhage and complete mucosal denudation.
Immunohistochemistry reveals deposition of complement proteins and IgM. Intestinal smooth muscle is more resistant to injury and demonstrates less disruption. As a result, perforation is a late complication, occurring in the most severe and late treated cases.
Remote injury
The severe local inflammatory injury to the intestine can be accompanied by a metabolic acidosis, and in humans disseminated intravascular coagulation. In addition, remote organ injury often occurs, and can manifest as profound hypotension, adult respiratory distress syndrome (ARDS), acute tubular necrosis (ATN), and hepatic failure. Histologically remote injury is often less severe, with increased vascular permeability, edema, and acute cellular infiltrate but less evidence of interstitial hemorrhage and necrosis.
Pathophysiology
It has long been known that the duration of ischemia before re-establishment of arterial blood flow directly affects the severity of the event, but it is during the reperfusion phase that the majority of injury takes place. This is generally true of all tissues. Reduction of ischemia time is an obvious avenue of prevention for physicians from cardiologists to transplant surgeons. It has been hypothesized that the extensive increase in tissue oxygen levels at reperfusion, together with the accumulation of certain metabolites during ischemia, such as hypoxanthines, lead to the rapid generation of oxygen free radicals which are immediately injurious to the tissue (2, 3) . This is accompanied by the release of eicosinoids, histamine, and thrombin into the circulation, as well as the generation of a number of interleukins, TNF, and active complement proteins. In addition complement proteins and IgM are deposited on the endothelium leading to further tissue damage, mediator release, and white cell recruitment.
Experimentally, we have shown that intestinal ischemia-reperfusion is dependent on the complement cascade. In order to understand why this mediator of our innate immune system would deposit in such tissue and lead to damage it is necessary to review this system.
The Complement system
The complement system is a cascade of more than twenty-five serum proteins and cellular receptors that work in concert to mediate inflammation, injury, and immunity. This phylogenetically ancient cascade has two major pathways: the classical, and the alternative. The first step in the classical pathway is formation of antibody-antigen complex as idiotypic F(ab) binds to its specific antigen on a cell surface (figure 1). As this occurs, it changes conformation and exposes an epitope in the immunoglobulin c-terminal end, the Fe region. The first component of complement, C Iq, avidly binds to this exposed region. C Iq is associated with two serine protease homo-dimers C Irand CIs, that are activated by binding to antibody and subsequently cleave C2 and C4, with the resultant fragments combining to form the powerful enzyme C4b2a, C3 convertase, adjacent to the Ab-antigen complex. C3 convertase cleaves C3 to form the C3b, which in turn binds to C3 convertase itself to form C4b2a3b, C5 convertase ( Figure 2 ). C5 convertase, C4b2a3b cleaves C5 to C5a and C5b. C5b transiently insert in the membrane and cleaves proteins C6 through C9, resulting in the formation of a membrane-associated heteropolymer, the C5b-9 membrane attack complex (MAC) (Fig. 3 ). This polymer becomes rapidly more lipophilic with each protein in its formation allowing it to insinuate itself in the plasma membrane of the stimulating cell. This acts as a ringlike pore, allowing ionic flux into the cell, and an obligate osmotic swelling. The concurrent increase in ionic calcium may also lead to cell activation. One MAC inserting into its lipid bilayer membrane (4) can lyse sheep erythrocytes. Nucleated cells usual require more complexes as they are better able to remove them by endo-and exocytosis (5). The alternative pathway is antibody independent. Polysaccharides and other microbial cell surface molecules can similarly bind and cleave C3 in conjunction with serum factor B, the resultant combination of fragments, C3bBb, is also C3 convertase (Fig. 4) . The C3b formed by either pathway convertase amplifies the cascade as C3b formed by C3 cleavage, produces more C3bBb and a second C5 convertase C3bBb3b.
It is known that complement deposition is a continuous process under normal conditions that is kept in check by regulatory mechanisms. C3b is formed at low levels by spontaneous hydrolysis of C3 both in the serum and on endothelial cell surfaces. Numerous circulating and surface bound regulatory proteins readily deactivate C3. It is only when the cascade is amplified or control mechanisms overwhelmed that the process leads to production of MAC and cell injury.
An important by product of the complement cascade is the production of powerful chemoattractants, most notably C3a and C5a. These circulating soluble anaphylatoxins act to recruit neutrophils to injured tissue and to activate them along with other locally released mediators such as histamine, thromboxane, and leukotrienes (6) . Membrane bound inactivated C3b, known as iC3b, has been shown to be an important signaling molecule for primed neutrophils leading to their activation (7) (8) (9) . Some complement proteins such as C3b, iC3b act as opsonins for neutrophils and macrophages which posses counter receptors on the cell surfaces known as CRl,CR2,CR3, and CR4. These direct phagocytosis and killing of dead or injured cells.
The complement system has long been recognized as a major defense mechanism against bacterial infection (10) . Patients with genetic deficiencies of essential complement components have an increased incidence of infection (11) . It is now also apparent that the complement system plays an integral role in immune surveillance. Complement mediates hyperacute rejection, the rapid host response vascular injury to xenografts and poorly matched allografts, producing obliteration of the vascular spaces in the graft within minutes (12) (13) (14) . By a similar mechanism, complement may playa role in immune surveillance of tumor cells, leading to recognition and removal of transformed cells. We believe that the complement system, acting in an analogous manner, plays a key role in ischemia reperfusion injury.
The role ofcomplement in intestinal ischemiareperfusion
Others and ourselves have demonstrated the requirement for complement to produce injury in many models of ischemia-reperfusion. We have shown that pre-treatment of rats with genetically engineered complement inhibitor, soluble complement receptor 1 (sCR 1), will significantly improve 5 day survival and protect against local injury (15) . CR 1 is a complement binding protein found on the surface of follicular dendritic cells and blood cells, including neutrophils and erythrocytes (16) . It plays an integral role in immune comnlex clearance as a result of its C3 binding ability. It also acts as a co-factor for factor I mediated cleavage of C3b and C4b, and accelerates decay of C3 and C5 convertases. It therefore is a powerful regulatory molecule for both alternative and classical pathway. Similarly sCR 1 induces global complement inhibition. In addition to intestinal ischemia reperfusion, sCR 1 is effective in reducing complement dependent local ischemiareeerfusion injury in other tissues such as myocardium (17) and skeletal muscle, (18) (19) and significantly increases graft survival of discordant xenografts (12) (13) (14) .
We have recently shown that sCR 1also protects against local injury in murine models of ischemia reperfusion, both in the hindlimb and in the intestine (20, 21) . By further studying mice genetically deficient in complement components we have more specifically interpreted the role of complement. We found that knockout mice deficient in C4 were as protected from local injury as were mice deficient in C3 in the hindlimb and intestinal model of IR; all complement deficient groups were similarly protected from injury as sCRI treated wildtype animals (20) (21) . This protection was shown by vascular permeability index and by immunohistochemistry (Fig. 5 ). These data demonstrate that the dependence on complement is via the classical pathway. Others have suggested that this classical pathway activation may be an antibody independent process, and that intracellular moieties exposed by ischemia may bind C 1q directly (22-23). However, Rag 1 mice deficient in IgM 
Fig. 7. Intestinal IR is dependent on IgMfrom BI cells. (A) CR2-/-shams. (B) CR2-/-IR: protected from injury. (C) WT IR: severe injury. (D) CR2-/-reconstituted with peritoneal B1 cells: injury is restored.
were similarly protected from injury, whereas Rag I animals reconstituted with pooled wildtype IgM had restoration of intestinal injury (21) (figure 5), again confirming the prominence of the classical pathway, which is most powerfully stimulated by IgM bound to antigen. We have further shown in the murine model of intestinal ischemia-reperfusion that injury is ultimately dependent on the membrane attack complex and not earlier mediators or anaphylatoxins. Mice deficient in C5 were protected from local injury. Injury was restored by reconstitution ofC5 deficient mice with wildtype serum prior to reperfusion (figure 6). By evaluating the role of neutrophils it was shown that this protection was due to the lack of C5b and the formation of MAC and not C5a. It has been suggested that C5a, a potent cherno-attractant particularly of neutrophils, might be an important mediator of such local injury. However, wildtype animals depleted of neutrophils were not protected from injury. In addition, C5 deficient animals though protected from injury had similar tissue levels of neutrophils as wildtypes (24) . Similarly, animals deficient in C5a receptor were not protected from injury (un pub lished).
Mechanism of complement deposition
These experiments in murine intestinal IR support our current model of this complement, IgM dependent injury. We believe that the initial event must be the subtle perhaps-reversible alteration of the ischemic tissue. It may be that free radicals generated during ischemia or early reperfusion damage or alter the cell surfaces in such a way that they express neo-antigen. The nature of this neoantigen(s) is presently unclear. The action of ischemia on these cells could be through other pathways. It may be that ischemia leads to minor alterations of the cell membrane, affecting lipids, carbohydrates, or proteins of the external surface such that these exposed epitopes are altered. Possibly, the cell membrane integrity could be challenged such that certain previously intracellular moieties are exposed, either the intercellular portion of surface molecules or other circulating intracellular products that escape to the surface. Any of these examples would represent the expression ofantigens that are not normally exposed to the immune system and therefore have never induced clonal deletion of their corresponding B cells during embryonic life. Therefore, whatever their nature these resultant neo-antigens are then identified and bound by circulating IgM isoantibodies producing an immune complex on the injured cell surface. IgM bound to antigen is the most potent trigger of the classical pathway as it readily binds Clq causing activation of its proteolytic partners Clr and CIs (figure 1). It is these active serine prdteases that cleave C4 and C2 triggering the classical cascade as described above.
The role of natural antibody
We have shown in both intestinal and hindlimb models that ischemia-reperfusion injury is mediated by IgM. It would be of profound significance to know the corresponding epitope as well as the source of the reactive antibody or antibodies. Although the specificity of neo-antigen is still uncertain, we now know the source of the antibody to be the B 1 cells.
The two possible sources of IgM are the Bland B2 cells. B2 cells are the classic B cells that in their mature form are found in the lymph tissue and spleen. They are renewed from bone marrow progenitors and may undergo clonal deletion and somatic rearrangement. B I cells are a unique subset ofB cells that are found in the mouse mostly in the peritoneum. They possess the marker CD5, and seem to undergo self-renewal. They have a limited IgM repertoire, yet have been frequently linked with self-reactive antibody and autoimmunedisease (25, 26, 27) .Utilizing knockout mice deficient in B1cells we have recently determined that the IgM responsible for triggering intestinal ischemia reperfusion injury is produced by these cells. Cr2-/-mice, knockout mice deficient in complement receptor 2, have a paucity ofB I cells. In addition they have an altered B I cell repertoire (28) . When subjected to intestinal ischemia reperfusion these mice were protected from injury compared to wildtypes despite normaltotal IgM. Cr2-/-reconstituted by wildtype B I cells from peritoneal lavage had a restoration of injury. These results were confirmed by immunohistochemistry ( figure 7 ). In addition, there was a significant increase in mortality in wildtype mice compared to Cr2 nulls from 20 to 80 percent (29) .This confirms our hypothesis that natural antibody produced by B1 cells binds to neo-antigen, triggers the classical pathway, and leads to local injury.
The role of neutrophils in local injury
We believe that local injury in our rat and murine models of intestinal ischemia reperfusion is not neutrophil dependent, as neutrophil depletion or inhibition of products of activated neutrophils such as free radicals and elastase are ineffective in modifying local events (30) . However, Granger et al have described a reduction of intestinal injury in a feline model of ischemia-reperfusion with neutrophil antagonism (31) . Our models, however, employ 100% ischemia whereas the above authors demonstrate only 80% ischemia. We carefully exclude collateral flow in our models. It may be that continuous low flow during ischemia allows an additional role for the neutrophil such as in our model of hindlimb ischemia in which there is flow via the medullary artery or in models of cardiac ischemia in which some endocardial perfusion occurs. In these models the neutrophil appears to playa significant role in local injury. This suggests that IR injury in each organ or tissue type may evolve in a different manner. It is also possible that the neutrophil plays a greater role in local injury depending on the time course, although, even in these other models, complement has been shown to playa central role.
The role of neutrophils and complement in remote injury
Neutrophils are believed to play an important role in remote injury to organs during intestinal ischemia-reperfusion. Rendering animals neutropenic prior to ischemia, or pretreatment with a monoclonal antibody directed against CD 18, either of which inhibit lung leukosequestration reduces lung permeability (30, 32) . Pre-treatment with monoclonal antibody to CD 11b or sCR 1 prevented lung injury but not leukosequestration (15, 33) . This is thought to be due to prevention of signaling of neutrophils via iC3b-CD11b interaction.
How complement is deposited in remote organs is unclear. It is clear that complement signaling of neutrophils is an important factor for remote injury. Further study of specific anti-anaphalotoxins and knockout mice should help to answer these questions.
Therapeutics
As we have shown complement plays a significant role in intestinal ischemia-reperfusion injury. In addition, broad inhibition of complement protects against injury. Yet as this is not the only function of the complement system, global inhibition of complement is not generally a satisfactory option; particularly in these already compromised patients. It is beyond the scope of this discussion to describe all the potential therapeutic targets. Each of the many elements ofthis system is a potential avenue of therapy. From targeting individual proteins to isolating and blocking the responsible antibody(s), there are many yet to be tried. By further, dissecting the mechanism of this injury it is our hope that a selective path can be found that will not harm our patients.
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